← Back to Search
Cancer Statistics, 2001
R. Greenlee, M. B. Hill-Harmon, T. Murray, M. Thun
Published 2001 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Each year the American Cancer Society compiles estimates of the number of new cancer cases and deaths expected in the US in the current year and the most recent data on cancer incidence, mortality, and survival. An estimated 1,268,000 new cases of cancer will be diagnosed in the year 2001 and an estimated 553,400 Americans will die from cancer. Overall cancer incidence and death rates have continued to decrease in men and women since the early 1990s, and the decline in overall cancer mortality has been greater in recent years. Despite reductions in age‐adjusted rates of cancer death, the total number of recorded cancer deaths in the US continues to increase, due to an aging and expanding population. Large disparities in cancer incidence and mortality across racial/ethnic groups continue. Black men and women experience higher incidence of cancer and poorer survival than white men and women. The disparity in survival reflects both diagnosis of cancer at later disease stages, and poorer survival within each stage of diagnosis.
This paper references
Multiple Cause-of-Death (inclusive of Underlying Cause of Death) for ICD-9 1997 Data Public-Use Documentation
Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking.
P. Wingo (1999)
An adjustment to the 1997 estimate for new prostate cancer cases
P. Wingo (1997)
P A Wingo
Trends in Five-Year Relative Cancer Survival Rates* (%) by Race and Year of Diagnosis, US
DEVCAN: Probability of Developing or Dying of Cancer (Software), version 4
E J Feuer (2000)
The annual report to the nation on the status of cancer, 1973–1997, with a special section on colorectal cancer
L. Ries (2000)
Submission. Bethesda, MD, US Department of Health and Human Services
[The National Cancer Institute].
This paper is referenced by
Serum Exosomal miR-941 as a promising Oncogenic Biomarker for Laryngeal Squamous Cell Carcinoma
Q. Zhao (2020)
Differential proteomic analysis of a human breast tumor and its matched bone metastasis identifies cell membrane and extracellular proteins associated with bone metastasis.
B. Dumont (2012)
Cu(OTf)2 catalyzed three component reaction: efficient synthesis of spiro[indoline-3,4'-pyrano[3,2-b]pyran derivatives and their anticancer potency towards A549 human lung cancer cell lines.
K. Parthasarathy (2013)
Mitochondrial DNA Haplogroup Analysis Reveals no Association between the Common Genetic Lineages and Prostate Cancer in the Korean Population
W. Kim (2008)
Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis.
D. Wei (2005)
Absence of L1 in pancreatic masses distinguishes adenocarcinomas from poorly differentiated neuroendocrine carcinomas.
J. Kaifi (2006)
Growth suppressing effect of garlic compound diallyl disulfide on prostate cancer cell line (PC-3) in vitro.
A. ArunKumar (2005)
Inhibition of CaMKII-mediated c-FLIP expression sensitizes malignant melanoma cells to TRAIL-induced apoptosis.
C. Xiao (2005)
Polymorphisms of the GSTM1, GSTP1, MPO, XRCC1, and NQO1 genes in Chinese patients with non-small cell lung cancers: relationship with aberrant promoter methylation of the CDKN2A and RARB genes.
E. Chan (2005)
Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines.
J. Ahn (2005)
Autofluorescence bronchoscopy with white light bronchoscopy compared with white light bronchoscopy alone for the detection of precancerous lesions: a European randomised controlled multicentre trial
K. Haeussinger (2005)
A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer.
K. Muro (2004)
Neoplasms of the liver and the bile ducts.
Haesun Choi (2004)
Increased expression of pro-inflammatory cytokines as a cause of lung toxicity after combined treatment with gemcitabine and thoracic irradiation.
C. Rübe (2004)
Iodine-131 tositumomab (Bexxar®): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin’s lymphoma
J. Friedberg (2004)
Isolated Limb Perfusion in Advanced Soft Tissue Sarcomas
P. Schlag (2007)
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.
P. Richardson (2004)
Adding Cytokines to Monoclonal Antibody Therapy: Does the Concurrent Administration of Interleukin-12 Add to the Efficacy of Rituximab in B-cell Non-Hodgkin Lymphoma?
S. Ansell (2003)
Detection of cancer-specific markers amid massive mass spectral data
W. Zhu (2003)
Modulation of DNA hypomethylation as a surrogate endpoint biomarker for chemoprevention of colon cancer
L. Tao (2004)
Tripartite motif-containing 29 as a novel biomarker in non-small cell lung cancer.
Xiaoming Song (2015)
Is Cisplatin Required for the Treatment of Non-Small-Cell Lung Cancer? Experience and Preliminary Results of a Phase I/II Trial with Topotecan and Vinorelbine
R. Stupp (2001)
Overexpression of OLC1, cigarette smoke, and human lung tumorigenesis.
Jingsong Yuan (2008)
Changes in the management and outcome of central nervous system involvement from ovarian cancer since 1994
G. Cormio (2011)
Intraoperative imprint cytology of sentinel nodes in breast cancer
E. Barranger (2004)
Visualizing Head and Neck Tumors in Vivo Using Near-Infrared Fluorescent Transferrin Conjugate
L. Shan (2008)
Dosimetric analysis of urinary morbidity following prostate brachytherapy (125I vs. 103Pd) combined with external beam radiation therapy
C. Chen (2001)
Classification Models for Detection of Lung Cancer Based on Nine Element Distribution of Urine Samples
C. Tan (2010)
MicroRNAs, ultraconserved genes and colorectal cancers.
S. Rossi (2010)
CHAPTER 22 – Nutrition and Breast Cancer
C. Rock (2001)
Melanoma screening with serial whole body photographic change detection using Melanoscan technology.
R. Drugge (2009)
Invasive Ability of Human Renal Cell Carcinoma Cell Line Caki-2 Is Accelerated by Gamma-Aminobutyric Acid, via Sustained Activation of ERK1/2 Inducible Matrix Metalloproteinases
T. Inamoto (2007)See more